05/21/2020 / By Lance D Johnson
There’s no better way to get the stock market climbing again than to pump billions of emergency taxpayer dollars into vaccine companies, while cutting safety regulations for new cell-manipulating, gene-altering biologics. This is exactly what President Donald Trump, the FDA, and the federal coronavirus task force seem to be doing. They are fast-tracking experimental injections through clinical trials so they can be distributed en masse with the assistance of the U.S. military.
The federal government is hastening the scientific process and therefore polluting and corrupting it. The President’s “warp speed” demands for mass-produced biologics will inevitably cause unintended consequences, as biologics are unavoidably unsafe. (1 Bruesewitz v. Wyeth LLC)
These inevitable vaccine injuries will no doubt be swept under the rug and be handled by the Department of Health and Human Services and the special master of the Vaccine Court. This system was set up in 1988 to pay off select families of vaccine-injured children while granting vaccine makers legal immunity, preserving faulty vaccine supply. To make matters worse, the HHS has recently admitted in court that the lawfully required safety studies have not been conducted to improve vaccine safety over the past thirty-two years.
To heighten the coercion, several governors have announced extended state-wide lockdowns and restrictions, claiming that there will be no going back to normal until a vaccine or pharmaceutical is widely available. This is medical coercion empowered by the force of government – the likes of which the world has not witnessed since the rise of the Nazis. Not only is the scientific process being bastardized, but state governments are being used to punish certain businesses and suppress the people, to coerce the population to comply with upcoming, fast-tracked biologics and gene therapy injections.
On January 11, Chinese authorities shared a genetic sequence of novel coronavirus with US vaccine company, Moderna. Just two days later, the National Institute of Allergy and Infectious Disease (NSAID) finalized the sequence for mRNA-1273, allowing Moderna to manufacture the sequence for clinical trials. The NSAID is governed by Dr. Anthony Fauci, the lead spokesman for the federal coronavirus task force, and the same man who helped fund the Wuhan Institute of Virology where China conducted controversial research on bats and coronavirus gain-of-function.
This sequence is not the only coronavirus mutation identified by scientists. This year, there have been over thirty coronavirus mutations identified, each circulating in different hemispheres and regions, eliciting various viral loads and gain-of-function properties, causing various symptoms, ranging from a mild cold to symptoms much more severe.
On March 23, it was declared that the vaccine wouldn’t be commercially available for 12 to 18 months; however, Moderna announced that it could be available for “emergency use” before the end of the year. Moderna was then awarded hundreds of millions of dollars to enable large scale production of mRNA-1273. The company announced a worldwide collaboration with a biotechnology company named Lonza, to manufacture up to 1 billion doses of mRNA-1273 per year.
Now, this is a new kind of vaccine that inserts lab-grown genetic RNA material into your body, forcing an invasion into your cells. After the RNA material invades your cells and hijacks your cell’s ribosomes, it forces the cells to produce viral components such as the iconic spike protein. This vaccine-augmented, self-replicating spike protein, produced within the cells, is intended to train the immune system to fight. This manipulation of cellular protein encoding will never be adequately studied for safety in clinical trials, for it’s real effects can only be observed in the population over time.
The government and the vaccine makers have already prepared this biological preparation for mass distribution long before it had ever been researched through any credible scientific process, long before it had ever passed any serology efficacy test, or passed any animal safety tests, including primate and ferret studies. In tests on guinea pigs, 20 percent suffered serious reactions within 43 days, mirroring similar results that were obtained on the infamous SARS vaccine trials that caused pulmonary immunopathology in animals upon subsequent infection.
This new RNA sequence is currently being tested on people and rushed through human clinical trials so it can be released onto populations that are currently being coerced to accept a “new normal” until this cell-hijacking, gene-altering Holy Grail vaccine is available.
According to the pharmaceutical-funded media, this Holy Grail has passed through Phase 1 with flying colors. The RNA viral sequence and its accompanying formulation (undisclosed) has elicited an immune response in a small group of human participants between the ages of 18 and 55 years. This vague news has caused the company’s stock valuation to surge to 29 billion, an astonishing valuation for a company that currently sells zero products.
Moderna is using the pharmaceutical-funded media to their advantage, blitzing the media with corporate success talk but providing little data on real life efficacy and safety. How will this hijacking of cellular protein production and forced augmentation of antibodies hold up over time and how does it affect human DNA?
Scientists at the NSAID, who developed the vaccine prototype, are usually quick to advertise their successes. They have made no comment on the phase 1 trial and are currently quiet on the matter. Moderna, on the other hand, trumpeted their phase 1 results, watching their stock market valuation soar. Their press release praised the development of “binding antibodies” and omitted the fact that only eight out of forty-five vaccine recipients have so far developed neutralizing antibodies – the kind that are needed. The antibody assessment comes after participants received two doses of the vaccines and had their blood tested two weeks later. The researchers will never know if these antibodies are durable, whether they will convey any form of short or long-standing immunity. Moreover, this new RNA encoding and its artificial augmentation of an immune response could have repercussions as the immune system could attack the body’s own cells. Could these RNA messenger immune augmentations ultimately generate strong type I interferon responses, leading to chronic inflammation and inflammatory conditions?
“I would like to see the data to make my own interpretation of the data,” said Anna Durbin, a vaccine researcher at Johns Hopkins University. “But I think it is at least encouraging that we’ve seen immune responses with this RNA vaccine that we haven’t seen with previous RNA vaccines for other pathogens. Whether it’s going to be enough, we don’t know.” Two weeks is very early, she said. “We don’t know if those antibodies are durable.”
Upon further investigation, the vaccine appears to trigger the production of “binding antibodies” that foreshadow the “pathogenic priming” that caused deaths in early SARS coronavirus vaccine experiments that failed to come to market during the 2002-2003 outbreak. Moreover, there is a 20% percent “serious” injury rate among the extremely healthy volunteers in the high dose group, which elicited medical intervention or hospitalization. Moderna has not disclosed whether the immune response they measured was more prevalent in the young or the old. Lastly, Moderna has not disclosed whether the immune response they measured is harmful upon subsequent infection, is capable of causing autoimmune issues, or causes damage to cellular processes that cannot be undone.
Sources include:
Tagged Under: binding antibodies, Clinical trials, coronavirus mutations, extended lockdowns, fast-tracked vaccine, gene alteration, inflammatory conditions, medical coercion, neutralizing antibodies, protein encoding, RNA messenger vaccines, safety studies, side effects, stock market, vaccine injury
PharmaceuticalFraud.com is a fact-based public education website published by Pharmaceutical Fraud Features, LLC.
All content copyright © 2018 by Pharmaceutical Fraud Features, LLC.
Contact Us with Tips or Corrections
All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.